Egypt

Egypt

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
3.61 (3.43 - 3.84) 2019 Modelled IHME
3.65 (3.47 - 3.86) 2018 Modelled IHME
3.72 (3.48 - 3.95) 2017 Modelled IHME
3.82 (3.60 - 4.04) 2016 Modelled IHME
3.93 (3.71 - 4.19) 2015 Modelled IHME
4.03 (3.82 - 4.27) 2014 Modelled IHME
4.13 (3.91 - 4.36) 2013 Modelled IHME
4.22 (3.98 - 4.46) 2012 Modelled IHME
4.3 (4.04 - 4.57) 2011 Modelled IHME
4.39 (4.10 - 4.68) 2010 Modelled IHME
4.46 (4.18 - 4.76) 2009 Modelled IHME
4.54 (4.27 - 4.84) 2008 Modelled IHME
4.61 (4.35 - 4.91) 2007 Modelled IHME
4.68 (4.41 - 4.98) 2006 Modelled IHME
4.75 (4.47 - 5.07) 2005 Modelled IHME
4.82 (4.55 - 5.13) 2004 Modelled IHME
4.89 (4.62 - 5.19) 2003 Modelled IHME
4.96 (4.69 - 5.26) 2002 Modelled IHME
5.02 (4.75 - 5.34) 2001 Modelled IHME
5.08 (4.78 - 5.41) 2000 Modelled IHME
5.13 (4.83 - 5.46) 1999 Modelled IHME
5.18 (4.88 - 5.51) 1998 Modelled IHME
5.23 (4.91 - 5.57) 1997 Modelled IHME
5.27 (4.94 - 5.62) 1996 Modelled IHME
5.31 (4.95 - 5.68) 1995 Modelled IHME
5.35 (5 - 5.72) 1994 Modelled IHME
5.39 (5.04 - 5.75) 1993 Modelled IHME
5.42 (5.06 - 5.80) 1992 Modelled IHME
5.46 (5.07 - 5.83) 1991 Modelled IHME
5.49 (5.07 - 5.88) 1990 Modelled IHME
1.96 (1.56 - 2.43) 2015 Modelled WHO
1.4 (1.20 - 1.60) 2015 Survey/reported Ismail et al, 2017
1 2015 Survey/reported Ministry of Health et al, 2015
1.71 (1.67 - 1.76) 2013 Modelled Schweitzer et al, 2015
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.11 (0.09 - 0.13) 2019 Modelled IHME
0.11 (0.09 - 0.14) 2018 Modelled IHME
0.12 (0.10 - 0.15) 2017 Modelled IHME
0.12 (0.10 - 0.15) 2016 Modelled IHME
0.12 (0.10 - 0.14) 2015 Modelled IHME
0.12 (0.10 - 0.14) 2014 Modelled IHME
0.12 (0.10 - 0.14) 2013 Modelled IHME
0.12 (0.10 - 0.14) 2012 Modelled IHME
0.12 (0.10 - 0.14) 2011 Modelled IHME
0.12 (0.10 - 0.14) 2010 Modelled IHME
0.12 (0.10 - 0.15) 2009 Modelled IHME
0.13 (0.10 - 0.15) 2008 Modelled IHME
0.14 (0.11 - 0.16) 2007 Modelled IHME
0.15 (0.12 - 0.18) 2006 Modelled IHME
0.16 (0.13 - 0.19) 2005 Modelled IHME
0.18 (0.14 - 0.21) 2004 Modelled IHME
0.2 (0.16 - 0.25) 2003 Modelled IHME
0.23 (0.19 - 0.28) 2002 Modelled IHME
0.26 (0.21 - 0.32) 2001 Modelled IHME
0.29 (0.23 - 0.35) 2000 Modelled IHME
0.31 (0.25 - 0.38) 1999 Modelled IHME
0.33 (0.26 - 0.40) 1998 Modelled IHME
0.34 (0.28 - 0.42) 1997 Modelled IHME
0.37 (0.29 - 0.45) 1996 Modelled IHME
0.4 (0.32 - 0.49) 1995 Modelled IHME
0.49 (0.39 - 0.61) 1994 Modelled IHME
0.68 (0.54 - 0.83) 1993 Modelled IHME
0.93 (0.75 - 1.14) 1992 Modelled IHME
1.24 (0.99 - 1.52) 1991 Modelled IHME
1.57 (1.26 - 1.93) 1990 Modelled IHME
0.8 (0.54 - 1.10) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
13 (9 - 19) 2019 Modelled IHME
13 (9 - 19) 2018 Modelled IHME
13 (9 - 19) 2017 Modelled IHME
13 (9 - 18) 2016 Modelled IHME
12 (9 - 18) 2015 Modelled IHME
13 (9 - 18) 2014 Modelled IHME
13 (9 - 18) 2013 Modelled IHME
13 (9 - 18) 2012 Modelled IHME
13 (9 - 18) 2011 Modelled IHME
13 (9 - 18) 2010 Modelled IHME
13 (9 - 18) 2009 Modelled IHME
13 (9 - 18) 2008 Modelled IHME
13 (9 - 18) 2007 Modelled IHME
13 (9 - 18) 2006 Modelled IHME
13 (9 - 18) 2005 Modelled IHME
13 (9 - 18) 2004 Modelled IHME
13 (10 - 18) 2003 Modelled IHME
14 (10 - 19) 2002 Modelled IHME
14 (10 - 19) 2001 Modelled IHME
14 (10 - 19) 2000 Modelled IHME
15 (10 - 20) 1999 Modelled IHME
15 (10 - 20) 1998 Modelled IHME
15 (11 - 21) 1997 Modelled IHME
15 (11 - 21) 1996 Modelled IHME
15 (11 - 21) 1995 Modelled IHME
15 (11 - 21) 1994 Modelled IHME
15 (11 - 21) 1993 Modelled IHME
15 (11 - 21) 1992 Modelled IHME
15 (11 - 21) 1991 Modelled IHME
15 (10 - 20) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
89 2018 Survey/reported WHO/UNICEF
84 2017 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
95 2018 Survey/reported WHO/UNICEF
94 2017 Survey/reported WHO/UNICEF
95 2016 Survey/reported WHO/UNICEF
93 2015 Survey/reported WHO/UNICEF
94 2014 Survey/reported WHO/UNICEF
97 2013 Survey/reported WHO/UNICEF
93 2012 Survey/reported WHO/UNICEF
96 2011 Survey/reported WHO/UNICEF
97 2010 Survey/reported WHO/UNICEF
97 2009 Survey/reported WHO/UNICEF
97 2008 Survey/reported WHO/UNICEF
98 2007 Survey/reported WHO/UNICEF
98 2006 Survey/reported WHO/UNICEF
98 2005 Survey/reported WHO/UNICEF
97 2004 Survey/reported WHO/UNICEF
98 2003 Survey/reported WHO/UNICEF
97 2002 Survey/reported WHO/UNICEF
99 2001 Survey/reported WHO/UNICEF
98 2000 Survey/reported WHO/UNICEF
97 1999 Survey/reported WHO/UNICEF
88 1998 Survey/reported WHO/UNICEF
81 1997 Survey/reported WHO/UNICEF
77 1996 Survey/reported WHO/UNICEF
74 1995 Survey/reported WHO/UNICEF
57 1994 Survey/reported WHO/UNICEF
Showing out of
Show more

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
Eligible for HBV generic medicines
HepB birth dose policy
Yes
Year of birth dose introduction
2015
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2020
Eligible for HCV generic medicines
HCV testing policy
Universal
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Some (11-30%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
1.98 (1.28 - 2.86) 2019 Modelled IHME
3.05 (2.32 - 3.95) 2018 Modelled IHME
3.77 (3 - 4.65) 2017 Modelled IHME
4.15 (3.35 - 5.06) 2016 Modelled IHME
4.44 (3.61 - 5.41) 2015 Modelled IHME
4.75 (3.91 - 5.69) 2014 Modelled IHME
5.07 (4.24 - 6.01) 2013 Modelled IHME
5.36 (4.50 - 6.34) 2012 Modelled IHME
5.59 (4.70 - 6.59) 2011 Modelled IHME
5.71 (4.80 - 6.76) 2010 Modelled IHME
5.76 (4.84 - 6.77) 2009 Modelled IHME
5.8 (4.87 - 6.82) 2008 Modelled IHME
5.83 (4.91 - 6.87) 2007 Modelled IHME
5.85 (4.91 - 6.91) 2006 Modelled IHME
5.85 (4.91 - 6.95) 2005 Modelled IHME
5.78 (4.85 - 6.84) 2004 Modelled IHME
5.59 (4.67 - 6.69) 2003 Modelled IHME
5.36 (4.45 - 6.46) 2002 Modelled IHME
5.17 (4.28 - 6.27) 2001 Modelled IHME
5.09 (4.20 - 6.19) 2000 Modelled IHME
5.1 (4.23 - 6.18) 1999 Modelled IHME
5.11 (4.26 - 6.19) 1998 Modelled IHME
5.13 (4.25 - 6.24) 1997 Modelled IHME
5.16 (4.25 - 6.27) 1996 Modelled IHME
5.19 (4.27 - 6.31) 1995 Modelled IHME
5.23 (4.32 - 6.37) 1994 Modelled IHME
5.3 (4.37 - 6.48) 1993 Modelled IHME
5.38 (4.42 - 6.62) 1992 Modelled IHME
5.48 (4.49 - 6.75) 1991 Modelled IHME
5.59 (4.57 - 6.95) 1990 Modelled IHME
6 2015 Survey/reported Egypt MoH et al, 2015
7.3 2013 Modelled Waked et al, 2013
8 2008 Survey/reported El-Zanaty F and Way A, 2008
15 1999 Survey/reported Abdel-Aziz F et al, 2000
6.3 (4.50 - 6.70) 2015 Modelled Blach et al, 2017
10 (7 - 12.20) 2014 Modelled Gower et al, 2014
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
8.5 2015 Survey/reported Egypt MoH et al, 2015
12 2008 Survey/reported El-Zanaty F and Way A, 2008
23.7 1999 Survey/reported Abdel-Aziz F et al, 2000
14.7 (10.30 - 18) 2014 Modelled Gower et al, 2014
14.7 (13.90 - 15.50) 2008 Survey/reported Guerra et al, 2012
Showing out of
Show more
People who inject drugs (PWID)
Download
Value (%) Year Type Source
49.4 (35.80 - 63) 1995 Modelled Nelson P et al, 2011

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
63 (54 - 71) 2019 Modelled IHME
64 (54 - 72) 2018 Modelled IHME
64 (54 - 72) 2017 Modelled IHME
64 (54 - 72) 2016 Modelled IHME
65 (55 - 73) 2015 Modelled IHME
65 (55 - 72) 2014 Modelled IHME
65 (55 - 72) 2013 Modelled IHME
65 (55 - 72) 2012 Modelled IHME
65 (55 - 72) 2011 Modelled IHME
65 (56 - 73) 2010 Modelled IHME
65 (56 - 73) 2009 Modelled IHME
65 (56 - 72) 2008 Modelled IHME
65 (56 - 72) 2007 Modelled IHME
65 (56 - 72) 2006 Modelled IHME
65 (57 - 72) 2005 Modelled IHME
65 (57 - 72) 2004 Modelled IHME
65 (57 - 72) 2003 Modelled IHME
65 (57 - 72) 2002 Modelled IHME
65 (56 - 72) 2001 Modelled IHME
65 (56 - 72) 2000 Modelled IHME
64 (56 - 71) 1999 Modelled IHME
64 (56 - 71) 1998 Modelled IHME
64 (55 - 71) 1997 Modelled IHME
64 (55 - 71) 1996 Modelled IHME
64 (55 - 71) 1995 Modelled IHME
64 (55 - 71) 1994 Modelled IHME
64 (56 - 71) 1993 Modelled IHME
64 (56 - 71) 1992 Modelled IHME
64 (56 - 72) 1991 Modelled IHME
65 (56 - 72) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
Eligible for HBV generic medicines
HepB birth dose policy
Yes
Year of birth dose introduction
2015
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2020
Eligible for HCV generic medicines
HCV testing policy
Universal
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Some (11-30%)

Overview

HBV elimination goal
HCV elimination goal
Year of goal
2020

Prevalence (national)

Modelled

HBV (HBsAg+)
3.61 (%)
2019
(3.43 - 3.84(%))
IHME
HCV (RNA/cAg+)
1.98 (%)
2019
(1.28 - 2.86(%))
IHME

Survey/surveillance

HBV (HBsAg+)
1.4 (%)
2015
(1.2 - 1.6(%))
Ismail et al, 2017
HCV (anti-HCV)
8.5 (%)
2015
Egypt MoH et al, 2015

Hepatitis related deaths (national)

Modelled

HBV
19,190
2019
(11,665 - 28,385)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
35,523
2019
(24,016 - 48,494)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.11 (%)
2019, latest modelled
(0.09 - 0.13(%))
IHME

Prevalence PWID

HCV
49.40 (%)
1995, latest modelled
(35.80 - 63(%))
Nelson P et al, 2011

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
89 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines

Resources